Molecular biology underlying the clinical heterogeneity of prostate cancer: An update

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 7, 2009, Pages 1033-1040

  Mackinnon, A Craig ^a   Yan, Benjamin C ^a   Joseph, Loren J ^a   Al Ahmadie, Hikmat A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; CANCER LOCALIZATION; CLINICAL TRIAL; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUSION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; GENE STRUCTURE; GENE TRANSLOCATION; GENETIC HETEROGENEITY; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MORPHOLOGY; NONHUMAN; ONCOGENE; PATHOLOGY; PREVALENCE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW;

GENETIC HETEROGENEITY; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSLOCATION, GENETIC;

EID: 67649805085     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859-864. (Pubitemid 36331852)
4. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality-part I: international comparisons. BJU Int. 2002;90: 162-173. (Pubitemid 34779587)
5. American Cancer Society. Cancer Facts and Figures, 2003. Atlanta, GA: American Cancer Society; 2003.
6. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168:906-913. (Pubitemid 34898295)
7. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992;89:3367-3371.
8. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin. 1997;47:273-287. (Pubitemid 27405933)
9. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337-347.
10. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58:196-213.
11. Alcaraz A, Takahashi S, Brown JA, et al. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 1994;54:3998-4002. (Pubitemid 24258100)
12. Bandyk MG, Zhao L, Troncoso P, et al. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer. 1994;9:19-27. (Pubitemid 2021025)
13. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res. 1996;56: 4150-4153. (Pubitemid 26305008)
14. Cunningham JM, Shan A, Wick MJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res. 1996;56:4475-4482. (Pubitemid 26330457)
15. Elo JP, Harkonen P, Kyllonen AP, et al. Loss of heterozygosity at 16q24.1- q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 1997;57:3356-3359. (Pubitemid 27355474)
16. Latil A, Baron JC, Cussenot O, et al. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer. 1994;11:119-125. (Pubitemid 24300186)
17. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res. 1997;57:1058-1062. (Pubitemid 27138601)
18. Saric T, Brkanac Z, Troyer DA, et al. Genetic pattern of prostate cancer progression. Int J Cancer. 1999;81:219-224. (Pubitemid 29144750)
19. Takahashi S, Shan AL, Ritland SR, et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 1995;55:4114-4119.
20. Van Den Berg C, Guan XY, Von Hoff D, et al. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res. 1995;1:11-18.
21. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res. 1994;54:6370-6373.
22. LaTulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62:4499-4506. (Pubitemid 34827314)
23. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227-235. (Pubitemid 30132189)
24. Coffey DS. Prostate cancer: an overview of an increasing dilemma. Cancer. 1993;71:880-886. (Pubitemid 23049609)
25. Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, Caggiula A. The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol. 1981;114:804-816. (Pubitemid 12246669)
26. Mawhinney MG, Neubauer BL. Actions of estrogen in the male. Invest Urol. 1979;16:409-420. (Pubitemid 9199452)
27. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999;59:4161-4164. (Pubitemid 29418717)
28. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
29. Huggins C, Hodges CV. Studies on prostatic cancer-I: The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232-240.
30. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973;32:1126-1130.
31. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244. (Pubitemid 41043794)
32. The Medical Research Council Prostate CancerWorking Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial-The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235-246.
33. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate: The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet. 1967;124:1011-1017.
34. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997;57:4687-4691. (Pubitemid 27468967)
35. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 1981;41:5070-5075. (Pubitemid 12196676)
36. Chang SS, Benson MC, Campbell SC, et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer. 2005;103:11-21. (Pubitemid 39665452)
37. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptormediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001;61:4315-4319. (Pubitemid 32685750)
38. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61:3550-3555. (Pubitemid 32694958)
39. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Uurol. 2000;164:1992-1995. (Pubitemid 30835440)
40. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45. (Pubitemid 33741879)
41. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997;3:1383-1388. (Pubitemid 27362400)
42. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene ampli- fication: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57:314-319. (Pubitemid 27036612)
43. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89:552-556. (Pubitemid 37026442)
44. Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol. 1997;11:450-459. (Pubitemid 27147013)
45. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990;173:534-540.
46. Han G, Buchanan G, Ittmann M, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A. 2005; 102:1151-1156. (Pubitemid 40170741)
47. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39. (Pubitemid 38524696)
48. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A. 2001;98:10823-10828. (Pubitemid 32878704)
49. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer-part 1: modifications to the androgen receptor. BJU Int. 2005;95:1320-1326. (Pubitemid 40799454)
50. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:265-271. (Pubitemid 40128247)
51. Culig Z, Steiner H, Bartsch G, Hobisch A. Mechanisms of endocrine therapy- responsive and -unresponsive prostate tumours. Endocr Relat Cancer. 2005; 12:229-244. (Pubitemid 40896443)
52. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. P300 regulates androgen receptor-independent expression of prostate-specific qantigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res. 2005; 65:5965-5973. (Pubitemid 40911204)
53. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer-part 2: androgen-receptor cofactors and bypass pathways. BJU Int. 2005;95:1327-1335. (Pubitemid 40799455)
54. Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol. 2002;250:1-23.
55. Costa RH, Kalinichenko VV, Lim L. Transcription factors in mouse lung development and function. Am J Physiol Lung Cell Mol Physiol. 2001;280:823L- 838L. (Pubitemid 32436045)
56. Kaestner KH. The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol Metab. 2000;11:281-285. (Pubitemid 30659554)
57. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000;14:142-146. (Pubitemid 30070978)
58. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate. 2006;66:1013-1028. (Pubitemid 43939204)
59. Tomaru Y, Kondo S, Suzuki M, Hayashizaki Y. A comprehensive search for HNF-3alpha-regulated genes in mouse hepatoma cells by 60K cDNA microarray and chromatin immunoprecipitation/PCR analysis. Biochem Biophys Res Commun. 2003;310:667-674. (Pubitemid 37163716)
60. Zaret K. Developmental competence of the gut endoderm: genetic potentiation by GATA and HNF3/fork head proteins. Dev Biol. 1999;209:1-10. (Pubitemid 29194308)
61. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217-227. (Pubitemid 38364606)
62. De Primo SE, Diehn M, Nelson JB, et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002;3: research0032.1.
63. Moore SM, Nelson PS. Gene expression profiling of the human prostate androgen response program. J Androl. 2002;23:163-169. (Pubitemid 34169270)
64. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 2002;99: 11890-11895. (Pubitemid 34994494)
65. Vaarala MH, Porvari K, Kyllonen A, Vihko P. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest. 2000;80:1259-1268. (Pubitemid 30637066)
66. Xu LL, Su YP, Labiche R, et al. Quantitative expression profile of androgenregulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer. 2001;92:322-328. (Pubitemid 32249705)
67. Amler LC, Agus DB, LeDuc C, et al. Dysregulated expression of androgenresponsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000;60:6134-6141. (Pubitemid 30839646)
68. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758-1764. (Pubitemid 29518772)
69. Mousses S,Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene. 2001;20:6718-6723. (Pubitemid 33020600)
70. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002;62:1008-1013. (Pubitemid 34160279)
71. Nagabhushan M, Miller CM, Pretlow TP, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 1996;56:3042-3046. (Pubitemid 26199749)
72. Wainstein MA, He F, Robinson D, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 1994;54:6049-6052. (Pubitemid 24378626)
73. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892-2898. (Pubitemid 32691931)
74. Chugh A, Ray A, Gupta JB. Squalene epoxidase as hypocholesterolemic drug target revisited. Progr Lipid Res. 2003;42:37-50. (Pubitemid 35428788)
75. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362. (Pubitemid 27147102)
76. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001;114:2375-2382. (Pubitemid 32684793)
77. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280-285. (Pubitemid 29124362)
78. Arai Y, Yoshiki T, Yoshida O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate. 1997;30:195-201. (Pubitemid 27149279)
79. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000;60:6841-6845. (Pubitemid 32059149)
80. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A. 1999;96:5458-5463. (Pubitemid 29234639)
81. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 2000;275:24500-24505. (Pubitemid 30626543)
82. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-566. (Pubitemid 28067285)
83. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-5478. (Pubitemid 24978134)
84. Jin RJ,Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 2004;64:5489-5495. (Pubitemid 39006573)
85. Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005;65:5153-5162. (Pubitemid 40827324)
86. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648. (Pubitemid 41528150)
87. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2: ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68: 73-80.
88. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions de- fine a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396-3400.
89. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003;303:11-34. (Pubitemid 36151767)
90. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005;41:2462-2478. (Pubitemid 41540623)
91. Korenchuk S, Lehr JE, MClean L, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001;15:163-168. (Pubitemid 32328191)
92. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177-188. (Pubitemid 351240884)
93. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
94. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-599. (Pubitemid 47206938)
95. Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics. 1997; 44:309-320. (Pubitemid 27419006)
96. Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999;59:4180-4184. (Pubitemid 29418721)
97. Vaarala MH, Porvari KS, Kellokumpu S, Kyllonen AP, Vihko PT. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol. 2001;193:134-140. (Pubitemid 32051123)
98. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia. 2006; 8:465-469. (Pubitemid 44035330)
99. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667-2673. (Pubitemid 46632014)
100. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 2006;45:717-719. (Pubitemid 43727158)
101. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66:8347-8351. (Pubitemid 44449142)
102. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene. 2008;27: 1993-2003.
103. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006;66: 10242-10246. (Pubitemid 44799738)
104. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538-544. (Pubitemid 46631996)
105. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66:8337-8341. (Pubitemid 44449140)
106. Schlesinger C, Bostwick DG, Iczkowski KA. High-grade prostatic intra- epithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol. 2005;29:1201-1207. (Pubitemid 41232993)
107. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol. 2007;212:91-101. (Pubitemid 46746294)
108. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2- ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008;14:3380-3385.
109. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826-832. (Pubitemid 44564838)
110. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888. (Pubitemid 47165141)
111. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253-263.
112. Gopalan A, Leversha M, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009. In press.
113. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a populationbased study of prostate cancer. BMC Cancer. 2008;8:230.
114. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26: 4596-4599. (Pubitemid 47037039)
115. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol. 2007;60:1238-1243. (Pubitemid 350084545)
116. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer. 2007;97:1690-1695. (Pubitemid 350249347)
117. Fine SW, Gopalan A, Al-Ahmadie HA, et al. Does TMPRSS2-ERG gene fusion status in prostate cancer correlate with Gleason score? Mod Pathol. 2008; 21:156A.
118. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 2007;20:467-473. (Pubitemid 46482370)
119. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in latestage androgen receptor-negative prostate cancer. Cancer Res. 2006;66:10658-10663. (Pubitemid 44876959)